Overview:
Chart the future of the global oncology market Explore the fiercely competitive oncology market with the most comprehensive resource available. Augment or build your models with deep, meticulously researched data - and expand your understanding of different drugs, classes and sub-classes.
Equip your team with 119 brand profiles, all of which contain painstaking detail:
-
Historical and projected sales from 2006-2015
-
Current and projected approvals
-
Critical clinical trials to watch
-
Analysis that places each drug in context against key competitors and market events
-
Patent, generics and litigation information
After scouring the profiles, gauge your resource levels: Brand spending data tracks real-world dollars for promotion, medical affairs, market access and more - information you won't find anywhere else.
Give your teams all the oncology market research they need to make critical product decisions!
Additional Information
Profiled Oncology Portfolios
Amgen
AstraZeneca
Bristol-Myers Squibb
Celgene
Eli Lilly (including ImClone)
Genzyme
GlaxoSmithKline
Johnson & Johnson
Merck (including Schering-Plough)
Novartis
Pfizer (including Wyeth)
Roche (including Genentech)
Sanofi-Aventis
All Companies Included in Report
Abbott
Abraxis
Allos Therapeutics
Amgen
AnGes
Antisoma
Ariad
ArQule
Array BioPharma
Astellas
AstraZeneca
Bayer
Bioenvision
Biovail
Bristol-Myers Squibb
Celgene
Cephalon
Chugai
Cougar
Daiichi Sankyo
Dendreon
Eisai
Eli Lilly
Enzon
Epicept
Exelixis
GenMab
Genzyme
GlaxoSmithKline
GTx
Infinity
Johnson & Johnson
Medivation
Merck
Merck KGaA
Millennium
Myriad
Nektar
Novartis
Oncothyreon
Onyx
OSI
Pfizer
PharmaMar
Poniard
Progenics
Regeneron
Roche
Sanofi-Aventis
Seattle Genetics
Sigma Tau
Taisho
Transgene
Vical
|
